Windlas Biotech H1FY27 Revenue Surges 18% to ₹512 Cr; PAT Grows 33%
Windlas Biotech reported H1FY27 revenue of ₹512 Cr (up 18% YoY) and H1FY27 PAT of ₹50 Cr (up 33% YoY). Q2FY27 revenue was ₹264 Cr (up 19% YoY) with PAT of ₹25 Cr (up 29% YoY). Plant 6 commercialized in Sep 2026. Company has ₹223 Cr net liquidity and is net debt-free.
The financial results show significant growth and profitability, coupled with strategic operational advancements, which are likely to positively impact investor confidence and the company's market position.
The company reported strong year-on-year growth in revenue and profits for both H1FY27 and Q2FY27, along with record EPS and positive operational developments like plant commercialization and EUGMP certification.
Windlas Biotech Limited has announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company reported its 15th consecutive quarter of record revenue, with H1FY27 revenue reaching ₹512 crores, an 18% year-on-year growth from ₹432 crores in H1FY26.
Adjusted EBITDA for H1FY27 stood at ₹70 crores, a 23% increase YoY, with an EBITDA margin of 13.7%. Adjusted Profit After Tax (PAT) grew by 33% YoY to ₹50 crores, achieving a PAT margin of 9.7%. The company also reported its highest ever Earnings Per Share (EPS) of ₹17.21 in H1FY27.
For the second quarter of FY27 (Q2FY27), revenue from operations was ₹264 crores, up 19% YoY from ₹222 crores in Q2FY26. Adjusted EBITDA for Q2FY27 was ₹36 crores (up 20% YoY), and Adjusted PAT was ₹25 crores (up 29% YoY), with PAT margins at 9.5%.
The Generic Formulations CDMO vertical remained the primary revenue driver, contributing approximately 82% to H1 and Q2 FY27 revenues, with growth of 32% and 34% YoY, respectively. The Trade Generics & Institutional vertical saw a decline of 31% and 30% YoY, while the Exports vertical grew by 46% and 26% YoY.
Key operational highlights include the commercialization of Plant 6 in September 2026 and receiving EUGMP Certificates for Plant-4 & Plant-5. The company maintained a strong net liquidity of ₹223 crores and remained net debt-free as of September 30, 2026. ROCE and ROE stood at 38% and 33% for H1FY27 (excluding Plant 6).
What to do with a filing like this
Windlas Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Windlas Biotech Limited. Read the original for the full detail.